Condition Directory

ALS clinical trials

Directory of U.S. ClinicalTrials.gov public records for ALS. Browse ALS recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

486

Shown on this page

Current sort

How ALS studies are organized in the registry

Listings appear under both the abbreviation ALS and the full name “amyotrophic lateral sclerosis,” and some related records use “motor neuron disease.” The total volume is modest, so browsing the unfiltered list is practical; expanded-access records also appear in this condition and are labeled as such in the study-type field.

Terms that often appear in related listings

amyotrophic lateral sclerosis motor neuron disease SOD1 expanded access

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 13–24 of 486 matching trials for ALS.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Paralysis; Quadriplegic, Quadraplegia, Tetraplegia, Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis (ALS), Brainstem Stroke, Paralysis, Brain-computer Interface
Interventions: Mind Extender (MindEx); Device
Lead sponsor: Nader Pouratian; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions: Acamprosate calcium; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Amyotrophic Lateral Sclerosis Type 4, Inherited Neurological Disorders of RNA Processing
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 5 Years to 120 Years
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AP-101, Placebo; Drug
Lead sponsor: AL-S Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Amyotrophic Lateral Sclerosis, ALS
Interventions: LAM-002A, Placebo; Drug · Other
Lead sponsor: IRulya Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: RAPA-501 Autologous T stem cells; Biological
Lead sponsor: Rapa Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Not listed
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: Tazbentetol; Drug
Lead sponsor: Spinogenix; Industry
Eligibility: 18 Years to 85 Years
U.S. locations: 16
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Dazucorilant 300 mg, Dazucorilant 150 mg, Placebo, Dazucorilant; Drug · Other
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • San Francisco, California • Neptune City, New Jersey + 1 more

Conditions: ALS - Amyotrophic Lateral Sclerosis
Interventions: B cell infusion; Biological
Lead sponsor: Mark Poznansky; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Interventions: neck exoskeleton controller; Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

About this ALS clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list ALS as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within ALS.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

ALS clinical trials

How ALS studies are organized in the registry

Filter and sort this condition

Live official records

MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System

Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing

A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

RAPA-501 Therapy for ALS

Developing New Ways to Detect Respiratory Impairment Early in ALS

AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis

Intermediate-size Patient Population Expanded Access Protocol

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS)

Using Gaze to Enable Head-neck Movements in Patients With Head Drop

About this ALS clinical trials directory page